A detailed history of Cubist Systematic Strategies, LLC transactions in Nkarta, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 116,128 shares of NKTX stock, worth $313,545. This represents 0.0% of its overall portfolio holdings.

Number of Shares
116,128
Previous 251,914 53.9%
Holding current value
$313,545
Previous $1.49 Million 64.78%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.52 - $8.0 $613,752 - $1.09 Million
-135,786 Reduced 53.9%
116,128 $524,000
Q2 2024

Aug 14, 2024

BUY
$5.27 - $10.82 $1.33 Million - $2.73 Million
251,914 New
251,914 $1.49 Million
Q2 2023

Aug 14, 2023

SELL
$2.19 - $5.17 $66,444 - $156,857
-30,340 Reduced 57.8%
22,153 $48,000
Q1 2023

May 15, 2023

SELL
$3.37 - $6.3 $523,633 - $978,900
-155,381 Reduced 74.75%
52,493 $186,000
Q4 2022

Feb 14, 2023

BUY
$5.14 - $14.35 $727,310 - $2.03 Million
141,500 Added 213.19%
207,874 $1.25 Million
Q3 2022

Nov 14, 2022

BUY
$12.27 - $18.39 $212,086 - $317,871
17,285 Added 35.21%
66,374 $873,000
Q2 2022

Aug 15, 2022

BUY
$7.77 - $19.44 $381,421 - $954,290
49,089 New
49,089 $605,000
Q1 2022

May 16, 2022

SELL
$8.66 - $14.99 $293,322 - $507,726
-33,871 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$12.79 - $26.88 $433,210 - $910,452
33,871 New
33,871 $520,000
Q3 2021

Nov 15, 2021

SELL
$26.67 - $38.76 $233,095 - $338,762
-8,740 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$23.94 - $36.68 $101,218 - $155,083
-4,228 Reduced 32.6%
8,740 $277,000
Q1 2021

May 17, 2021

BUY
$31.33 - $59.61 $406,287 - $773,022
12,968 New
12,968 $427,000

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $131M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.